CHRONIC SPONTANEOUS URTICARIA

This study looks at the long-term safety and effectiveness of remibrutinib, an experimental drug, for adults with chronic spontaneous urticaria (CSU) — a condition causing frequent hives and itching without a clear trigger. About 696 participants who completed earlier phase 3 tri…

This study tests whether ritlecitinib, a drug already approved for another condition, can safely reduce hives and itching in people with chronic spontaneous urticaria (hives lasting over 6 weeks). Participants take the drug for 12 weeks and track their symptoms daily. The trial w…

This study tests a new drug, omalizumab α, against the approved drug Xolair for people with chronic hives that don't get better with antihistamines. About 392 adults aged 15 to 75 will receive either drug for 12 weeks to see how well it reduces itching and hives. The goal is to f…

This study tests an experimental drug called briquilimab in adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with usual antihistamines or omalizumab. The goal is to see if the drug is safe and can reduce symptoms by targeting …

This study tests a new drug called barzolvolimab for people with chronic spontaneous urticaria (long-term hives and itching) that antihistamines don't control. About 963 adults will receive either the drug or a placebo to see if it reduces hives and itching over 12 weeks. The goa…

This study tests a single dose of LP-003 in 12 healthy adults to see if it is safe and how the body processes it. The drug is being developed to help people with chronic spontaneous urticaria, a condition causing long-term hives and itching. The main goal is to check for side eff…

This study tests a new drug called barzolvolimab for adults with chronic spontaneous urticaria (long-term hives) that still cause symptoms despite taking antihistamines. About 976 participants will receive either the drug or a placebo to see if it reduces itching and hives over 1…

This study tests a new drug called EVO756 in 160 adults with moderate to severe chronic spontaneous urticaria (CSU), also known as chronic hives. Participants must have had hives for at least 3 months and not gotten enough relief from standard antihistamines. The goal is to see i…

This study tests a new daily pill, remibrutinib, for adults with chronic spontaneous urticaria (long-term hives and itching) that antihistamines can't control. About 470 participants will receive either remibrutinib, a placebo, or an active control (omalizumab injections) for up …

This early-stage study tests a new drug, BGB-16673, in adults with chronic spontaneous urticaria (long-lasting hives with no clear trigger). The main goal is to check safety and how the drug moves through the body. About 34 participants will receive either the drug or a placebo, …

This study is creating a large registry of up to 15,000 adults and children with inflammatory skin conditions like eczema, psoriasis, and vitiligo. Researchers will follow participants over time to see how treatments work in everyday medical practice and track any side effects. T…